Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
Lisa Vermij, Jan J. Jobsen, Alicia León‐Castillo, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 7, pp. 1360-1368
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
International Journal of Gynecology & Obstetrics (2023) Vol. 162, Iss. 2, pp. 383-394
Open Access | Times Cited: 500
FIGO staging of endometrial cancer: 2023
Jonathan S. Berek, Xavier Matías‐Guiu, Carien L. Creutzberg, et al.
Journal of Gynecologic Oncology (2023) Vol. 34, Iss. 5
Open Access | Times Cited: 131
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

International Journal of Gynecological Cancer (2022) Vol. 33, Iss. 1, pp. 109-117
Open Access | Times Cited: 108
Applications and Techniques of Machine Learning in Cancer Classification: A Systematic Review
Abrar Yaqoob, Rabia Musheer Aziz, Navneet Kumar Verma
Human-Centric Intelligent Systems (2023) Vol. 3, Iss. 4, pp. 588-615
Open Access | Times Cited: 62
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
Nanda Horeweg, Remi A. Nout, Ina M. Jürgenliemk‐Schulz, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 27, pp. 4369-4380
Open Access | Times Cited: 50
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma
Eric Rios‐Doria, Amir Momeni Boroujeni, Claire F. Friedman, et al.
Gynecologic Oncology (2023) Vol. 174, pp. 262-272
Open Access | Times Cited: 46
Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications
Francesca Addante, Antonio d’Amati, Angela Santoro, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1056-1056
Open Access | Times Cited: 17
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
Richard Schwameis, Francesco Fanfani, Christoph Ebner, et al.
European Journal of Cancer (2023) Vol. 193, pp. 113317-113317
Open Access | Times Cited: 42
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
Ye Yang, Su Fang Wu, Wei Bao
International Journal of Gynecology & Obstetrics (2023) Vol. 164, Iss. 2, pp. 436-459
Open Access | Times Cited: 38
Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer
Amy Jamieson, Jutta Huvila, Samuel Leung, et al.
Gynecologic Oncology (2023) Vol. 170, pp. 282-289
Closed Access | Times Cited: 23
Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection
Natalia Galant, Paweł Krawczyk, Marta Monist, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5893-5893
Open Access | Times Cited: 15
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere
Ilan Bruchim, Ilaria Capasso, Ariel Polonsky, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 1-2, pp. 29-43
Closed Access | Times Cited: 9
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
Carien L. Creutzberg, Jae‐Weon Kim, Gemma Eminowicz, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. e420-e431
Closed Access | Times Cited: 9
Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers
Luigi Antonio De Vitis, Fiorella E. Reyes-Baez, Gabriella Schivardi, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 81-88
Closed Access | Times Cited: 1
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
Michael D. Toboni, Kaitlyn Dinkins, Sharon Wu, et al.
Gynecologic Oncology (2025) Vol. 193, pp. 89-97
Closed Access | Times Cited: 1
Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
Amy Jamieson, Lisa Vermij, Claire J.H. Kramer, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 23, pp. 4949-4957
Open Access | Times Cited: 20
Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis
Zhi Xiong Chong, Chean Yeah Yong, Han Kiat Ong, et al.
Toxicology (2023) Vol. 495, pp. 153596-153596
Open Access | Times Cited: 18
Molecular profile is a strong predictor of the pattern of recurrence in patients with endometrial cancer
Ana Luzarraga Aznar, Vicente Bebia, Carlos López-Gil, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 5, pp. 659-666
Closed Access | Times Cited: 8
Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
Kristina Lindemann, Wanja Kildal, Andreas Kleppe, et al.
European Journal of Cancer (2024) Vol. 200, pp. 113584-113584
Closed Access | Times Cited: 7
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging
Íñigo Espinosa, Emanuela D’Angelo, Jaime Prat
Gynecologic Oncology (2024) Vol. 186, pp. 94-103
Closed Access | Times Cited: 7
Translating biological insights into improved management of endometrial cancer
Jeffrey How, Amir A. Jazaeri, Shannon N. Westin, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 11, pp. 781-800
Closed Access | Times Cited: 6
Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype
Jutta Huvila, Emily F. Thompson, Jamie Vanden Broek, et al.
Histopathology (2023) Vol. 83, Iss. 6, pp. 880-890
Open Access | Times Cited: 15
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification
Emanuele Perrone, Ilaria Capasso, Francesca De Felice, et al.
European Journal of Cancer (2023) Vol. 186, pp. 98-112
Closed Access | Times Cited: 14
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
Elisa D’Agostino, Luciana Mastrodomenico, Ornella Ponzoni, et al.
Cancer Treatment Reviews (2024) Vol. 126, pp. 102723-102723
Closed Access | Times Cited: 5
Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
Gian Franco Zannoni, Angela Santoro, Damiano Arciuolo, et al.
Gynecologic Oncology (2024) Vol. 189, pp. 98-100
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top